ImmunoPhotonics
4320 Forest Park Avenue
Suite 303
St. Louis
Missouri
63108
United States
Website: http://www.immunophotonics.com/
About ImmunoPhotonics
Immunophotonics is a biotech company developing a proprietary drug for use in a therapeutic cancer vaccine (inCVAX). This novel immunotherapy begins with a two injection procedure into any one accessible tumor, intended to liberate and utilize the patient’s tumor antigens to generate a systemic antitumor immune response.YEAR FOUNDED:
2009
LEADERSHIP:
Founder and CEO: Tomas Hode, PhD
COO Lu Alleruzzo, MBA
CDO (Chief Drug Dev. Officer): Joe Raker, PhD
FOLLOW IMMUNOPHOTONICS:
Tweets by Immunophotonics
2 articles with ImmunoPhotonics
-
St. Louis, Missouri is one of the fastest-growing and top-ranked emerging life sciences markets in the U.S., ranking sixth in a recent CBRE Research report.
-
ImmunoPhotonics Announces First Patient Dosed In A Randomized, Controlled Breast Cancer Clinical Trial For Incvax – A Novel Investigational Immuno-Oncology Therapy
8/23/2016